[unable to retrieve full-text content]CoinspeakerJohnson & Johnson Reports Better than Expected Q2 2023 Earnings, JNJ Shares Up Slightly The pharmaceutical segment reported the highest sales with about .71 billion, followed by MedTech with a total sales of about .78 billion, and the remaining accrued from the consumer health segment. Johnson & Johnson Reports Better than Expected Q2 2023 Earnings, JNJ Shares Up Slightly
Topics:
Steve Muchoki considers the following as important: Business News, jnj, jnj stock, johnson & johnson stock, Market News, News, Stocks, Wall Street
This could be interesting, too:
Temitope Olatunji writes X Empire Unveils ‘Chill Phase’ Update: Community to Benefit from Expanded Tokenomics
Bhushan Akolkar writes Cardano Investors Continue to Be Hopeful despite 11% ADA Price Drop
Bena Ilyas writes Stablecoin Transactions Constitute 43% of Sub-Saharan Africa’s Volume
Chimamanda U. Martha writes Crypto Exchange ADEX Teams Up with Unizen to Enhance Trading Experience for Users
Coinspeaker
Johnson & Johnson Reports Better than Expected Q2 2023 Earnings, JNJ Shares Up Slightly
The pharmaceutical segment reported the highest sales with about $13.71 billion, followed by MedTech with a total sales of about $7.78 billion, and the remaining accrued from the consumer health segment.
Johnson & Johnson Reports Better than Expected Q2 2023 Earnings, JNJ Shares Up Slightly